louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02087215: Effect of Local Application of Boron on Diabetic Foot Ulcers
Official title: Prospective Randomized Study of Local Application of Boron on Diabetic Foot Ulcers: Effect of Healing Process
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Diabetic Foot Ulcer
Keywords: diabetes mellitus
foot ulcer
boron
wound care
Lead sponsor: Bezmialem Vakif University
Sponsor class: OTHER
First posted: 2014-03-14
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Boron as a naturally occurring element has some metabolic and inflammatory actions. The antibacterial activity against gram negative bacteria is also known. Boron deficiency is shown to be related with impaired wound bone healing in rats. Therefore, special wound care formulas containing boron may have some positive effect on wound healing of the patients with diabetic foot ulcers.

Detailed description: Local treatment of diabetic foot ulcers:

1. Classification of International Working Group of the Diabetic Foot (IWGDF)
2. pre-treatment measurements including diameter and area
3. pre-treatment laboratory values including fasting glucose, hemoglobin, hemoglobin A1c, leucocyte count and c-reactive protein
4. pre-treatment wound culture
5. treatment either by placebo gel containing polymer of carbopol ultrex (1%) or by formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v).
6. post-treatment measurements and values

Eligibility criteria: Inclusion Criteria:

* diabetic food ulcer classified byInternational Working Group of the Diabetic Foot (IWGDF) as grade 1 and 2

Exclusion Criteria:

* previous vascular surgery on the side that the ulcer is present
* uncontrolled diabetes mellitus
* presence of osteitis, abscess, osteomyelitis, gangrene on the side that the ulcer is present
* diabetic food ulcer classified byInternational Working Group of the Diabetic Foot (IWGDF) as grade 3

Primary outcomes:
measure: number of the participants with complete epithelization of diabetic foot ulcer
timeFrame: up to 4 weeks
Secondary outcomes:
measure: number of participants in whom local infective complications develop in diabetic foot ulcer patients
timeFrame: up to 4 weeks
Other outcomes:
measure: improvement of inflammatory parameters in diabetic foot ulcers
timeFrame: up to 4 weeks
Locations:
city: Istanbul
country: Turkey
facility: Mustafa Hasbahceci
Study officials:
affiliation: bezmialem vakif university faculty of medicine dept of general surgery
name: mustafa hasbahceci, md
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04411615: Effect of Re-esterified Triglyceride (rTG) Form Omega-3 Supplements on Dry Eye Following Cataract Surgery
Official title: Effect of Re-esterified Triglyceride (rTG) Form Omega-3 Supplements on Dry Eye Following Cataract Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Dry Eye
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2020-06-02
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the clinical outcomes of the systemic re-esterified triglyceride (rTG) form of omega-3 fatty acids in patients with dry eye symptoms after cataract surgery


Eligibility criteria: Inclusion Criteria:

* Non complicated cataract surgery
* Patients with dry eye symptom

Exclusion Criteria:

* Using steroid eyedops,
* Using antibiotics eyedrops
* Surgery other than Cataract surgery
* Contact lens wearer
* Other systemic disease

Primary outcomes:
measure: Dry eye symptom
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Park J, Yoo YS, Shin E, Han G, Shin K, Lim DH, Chung TY. Effects of the re-esterified triglyceride (rTG) form of omega-3 supplements on dry eye following cataract surgery. Br J Ophthalmol. 2021 Nov;105(11):1504-1509. doi: 10.1136/bjophthalmol-2020-317164. Epub 2020 Sep 11.
Clinical trial NCT05125315: Intraoperative Hemodynamics in CABG
Official title: Intraoperative Hemodynamics in Patients Undergoing Coronary Artery Bypass Graft for Long-term Outcom
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Coronary Artery Disease
Lead sponsor: Beijing Anzhen Hospital
Sponsor class: OTHER
First posted: 2021-11-18
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergoing isolated CABG will included in this study. All the ertracted patients are ethnic Chinese. Patients undergoing emergency surgery or using ECOM/VAD will be excluded.

Brief summary: The study is to determine the effects of the intraoperative hemodynamics in patients undergoing coronary artery bypass graft on the short-term and long-term outcomes.


Eligibility criteria: Inclusion Criteria:

* age18-80 for CABG surgery only

Exclusion Criteria:

* Emergency surgery atrial fibrillation using ECMO/VAD

Primary outcomes:
measure: long-time motality after CABG
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04054115: Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow
Official title: The Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow After the Bidirectional Cavopulmonary Connection
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Congenital Heart Disease
Lead sponsor: The Hospital for Sick Children
Sponsor class: OTHER
First posted: 2019-08-13
Enrollment: 10
Sex: ALL
Minimum age (years): 1
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Patients with a bidirectional Glenn in their Pre-Fontan evaluation.
Primary purpose: TREATMENT

Brief summary: The second stage operation towards single ventricle palliation is 'bidirectional cavopulmonary connection' (BCPC). The superior vena cava is connected to the pulmonary artery, diverting 'blue' blood from the upper body (including the brain) to the lungs. A successful BCPC requires sufficient and easy blood flow through the lungs. Alprostadil is the synthetic form of prostaglandin (hormone that causes dilation of blood vessels) and has been shown to increase blood flow in the brain hence increasing blood flow to the lungs after BCPC, potentially useful in managing children post BCPC with low flow to the lungs and thus poor oxygenation. This study propose to investigate acute effects of Alprostadil on different blood vessels after BCPC.


Eligibility criteria: Inclusion Criteria:• BCPC patients at time of routine pre-Fontan assessment: Cardiac catheterization and cardiac magnetic resonance imaging (CMR)

• Patients between the ages of 1 and 6 years old.

Exclusion Criteria:

* Patients who are hypersensitive to this product or to any ingredient in its formulation.
* Patients with seizure disorders or coagulopathies.
* Patients with abnormal kidney function.

Primary outcomes:
measure: Cerebral blood flow
timeFrame: will be measured 30 minutes to 40 minutes after infusion of alprostadil
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Hospital for Sick Children
state: Ontario
Study officials:
affiliation: The Hospital for Sick Children
name: Rajiv Chaturvedi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00086515: Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
Official title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetes Mellitus, Type II
Keywords: Type 2 Diabetes Mellitus
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2004-07-05
Enrollment: 701
Sex: ALL
Minimum age (years): 18
Maximum age (years): 78
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.


Eligibility criteria: Inclusion Criteria:

* Patients with type 2 diabetes mellitus

Primary outcomes:
measure: Change From Baseline in Hemoglobin A1C (A1C) at Week 24
timeFrame: Baseline and Week 24
Secondary outcomes:
measure: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
timeFrame: Baseline and Week 24
measure: Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24
timeFrame: Baseline and Week 24
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006 Dec;29(12):2638-43. doi: 10.2337/dc06-0706.
citation: Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab. 2008 Dec;10(12):1212-20. doi: 10.1111/j.1463-1326.2008.00887.x. Epub 2008 May 12.
Clinical trial NCT02020915: Ultrasound Guided Lateral Sphincterotomy: Long Term Results
Official title: Ultrasound Guided Lateral Sphincterotomy: Long Term Results
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Focus: Anal Incontinence After Lateral Sphincterotomy for Chronic Anal Fissure
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
First posted: 2013-12-25
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing lateral sphincterotomy for chronic anal fissure

Brief summary: Ultrasound guided placement of the knife intersphincteric increases accuracy and safety during sphincterotomy. Secondly 3-D ultrasound visualizes that the internal anal sphincter is divided.


Eligibility criteria: Inclusion Criteria:

Patients undergoing lateral sphincterotomy for chronic anal fissure

Exclusion Criteria:

* Previous diltiazem treatment og botox injections were not performed

Primary outcomes:
measure: Anal incontinence
timeFrame: 5 years or more
Secondary outcomes:
measure: Healing of fissure
timeFrame: 5 years or more
Other outcomes:
Locations:
city: Hvidovre
country: Denmark
facility: Hvidovre University Hospital
Study officials:
References:
Clinical trial NCT00502515: Dose-effect of SSR180575 in Diabetic Neuropathy
Official title: A Multi-center, Randomized, Double-blind, Placebo Controlled Study of the Effect of SSR180575 at Two Doses for 24 Weeks Treatment on the Rate of Regeneration of Epidermal Nerve Fibers in Patients With Mild Diabetic Peripheral Neuropathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetic Neuropathies
Keywords: Diabetes
Neuropathy
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2007-07-17
Enrollment: 309
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this sudy is to assess the effect of two doses of SSR180575 on the rate of regeneration of epidermal nerve fibers following denervation of the epidermal layer with capsaicin in patients with diabetes mellitus and mild peripheral neuropathy. Secondary objectives are to explore the efficacy of SSR180575 on clinical assessment, nerve function measures and to assess the tolerability and safety of SSR180575. The treatment period is 6 months.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with Diabetes Mellitus, type I or II, treated or untreated
* Diabetic neuropathy treated or untreated

Exclusion Criteria:

* Patients with unstable glycemic control
* Patients who have been hospitalized for a diabetes complication in the 3 months prior to randomization
* Patients with peripheral neuropathy attributable to any cause other than diabetes
* Non-measurable sural nerve sensory response on nerve conduction studies
* Amputation of any part of lower extremity
* Patients with a history of myocardial infarction or known coronary artery disease
* Grade III or IV heart failure on New York Heart Association criteria

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Rate of epidermal nerve fiber regeneration
timeFrame: 24 weeks
Secondary outcomes:
measure: Efficacy: change between baseline and 24 weeks of peripheral neuropathy assessed with nerve conduction studies, clinical evaluation, Total Neuropathy Score
timeFrame: 24 weeks
measure: Safety: physical examination, clinical laboratories, adverse event reporting
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Bridgewater
country: United States
facility: Sanofi-Aventis Administrative Office
state: New Jersey
Study officials:
affiliation: Sanofi
name: ICD CSD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05517915: Inspiratory Muscle Training, Autonomic Dysfunction and Blood Pressure
Official title: Effect of Interval Inspiratory Muscle Training on Autonomic Dysfunction and Blood Pressure in Hypertensive Adults: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Keywords: Interval Inspiratory Muscle Training
Hypertension
Autonomic Dysfunction
Blood Pressure
Lead sponsor: King Saud University
Sponsor class: OTHER
First posted: 2022-08-26
Enrollment: 28
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two group pretest-posttest parallel design.
Primary purpose: TREATMENT

Brief summary: This study finds the effectiveness of inspiratory muscle threshold loading training among adults with hypertension. A sample of hypertensive subjects was divided into two groups - inspiratory muscle training (IMT) - group (inspiratory muscle training was prescribed) and sham-group (no load was prescribed during IMT). Both groups had training sessions comprising seven cycles of two minutes bouts of breathing counter to an inspiratory load, each bout parted by one minute of unloaded recovery. Treatment session was performed for three times per week for a total of six weeks. Measurement of each of the variables (blood pressure, resting heart rate (RHR), heart rate variability (HRV)) was taken at baseline and after the six-week intervention.

Detailed description: The present study aimed to examine the outcome of interval inspiratory muscle training at 70% load on blood pressure, resting heart rate and autonomic dysfunction in the hypertensive adults.

Participants were divided into two groups: IMT and sham. In IMT group, the threshold loading inspiratory muscle trainer from POWERbreathe was used with 70% IMT threshold. In Sham group, IMT was unloaded.

Eligibility criteria: Inclusion Criteria:

* stage 1 hypertension
* essential hypertension
* mild hypertension

Exclusion Criteria:

* Subjects participating in exercise training for more than the last six months
* severe musculoskeletal limitations
* severe neurological limitations
* cognitive impairments
* uncontrolled diabetes
* uncontrolled hypertension
* a history of myocardial infarction (MI)
* a history of stroke in the last six months
* unstable angina
* chronic heart failure
* pulmonary disease of any etiology

Primary outcomes:
measure: Resting heart rate
timeFrame: 6 weeks
measure: Autonomic functions
timeFrame: 6 weeks
measure: Blood pressure
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
facility: King Saud University
Study officials:
affiliation: King Saud University
name: Masood Khan, M.P.Th
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00519415: Comparative Results of Maxillary Deficiency Treatment by Tongue Plate and Facemask in Growing Patients
Official title: This Study is to Apply the Tongue Force to Correct the Dentofacial Deformities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Maxillary Deficiency
Keywords: Tongue plate
Facemask
class III maxillary deficiency
orthodontic angle class three
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2007-08-22
Enrollment: 20
Sex: ALL
Minimum age (years): 8
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A new appliance will be used to transfer the tongue force during its physiological activity to advance the nasomaxillary complex; this method will be compared with the traditional method which uses a Facemask appliance.

Detailed description: The above method will be compared with traditional one which uses the Facemask in combination with an intra-oral appliance.

Eligibility criteria: Inclusion Criteria:

* Growing patients
* Class III with maxillary deficiency

Exclusion Criteria:

* Previous orthodontic treatment
* Un cooperative patients

Primary outcomes:
measure: Cephalometric angles and clinical features
timeFrame: At least 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Shaheed Beheshti dental school
Study officials:
affiliation: Shaheed Beheshti dental school
name: Lida Toomarian
role: STUDY_CHAIR
affiliation: Shaheed Beheshti dental shool
name: Rahman Showkatbakhsh
role: STUDY_DIRECTOR
affiliation: Shaheed Beheshti dental shool
name: Mahkameh Mirkarimi
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01555385: The Effects of Breakfast on Mental Workload
Official title: The Effects of Nutritive and Non-nutritive Breakfast on Subjective Mental Workload During Multitasking - a Pilot Study in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Subjects
Keywords: Mental workload
Multitasking
Protein
Tryptophan
Lead sponsor: University of Helsinki
Sponsor class: OTHER
Collaborators: name: Finnish Institute of Occupational Health
name: SalWe Ltd.
First posted: 2012-03-15
Enrollment: 13
Sex: ALL
Minimum age (years): 22
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the study is to investigate the influence of nutritive (high-protein or high-carbohydrate) and non-nutritive (low energy) breakfast on psychological and physiological responses of mental workload during multitasking in healthy volunteers.


Eligibility criteria: Inclusion Criteria:

* eats usually breakfast
* use computer mouse with right hand
* normal sleep-wake rhythm between 9 pm and 8 am
* in females hormonal contraception

Exclusion Criteria:

* gastrointestinal disease, diabetes or any other significant major medical morbidity
* milk allergy
* lactose intolerance
* smoking
* excess use of alcohol, coffee, tea, cola drinks (\> 10 doses/day)
* pregnancy and breast feeding
* no medication or dietary supplements influencing measured responses
* BMI \> 30 kg/m2 or \< 18 kg/m2

Primary outcomes:
measure: Brain measures of mental workload (ERP 300 amplitude and latency) and heart rate
timeFrame: 1 day
Secondary outcomes:
measure: Subjective mental workload and mood measurement assessed using visual analogue scale in response to test meal.
timeFrame: 1 day
measure: cognitive function measurements
timeFrame: 1 day
measure: Blood concentration of glucose
timeFrame: 1 day
measure: salivary cortisol
timeFrame: 1 day
measure: Blood concentration of tryptophan in relation to other large neutral amino acids
timeFrame: 1 day
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: University of Helsinki, Institute of Biomedicine
Study officials:
References:
Clinical trial NCT01395485: Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescent (12 to <18 Years) and Adult Subjects With Intermittent or Mild to Moderate Persistent Asthma
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Asthma
Keywords: Amgen
Adolescent
Single Dose
Safety
Pharmacokinetics
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2011-07-15
Enrollment: 0
Sex: ALL
Minimum age (years): 12
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics in adolescent and adult subjects with intermittent or mild to moderate persistent asthma.


Eligibility criteria: Inclusion Criteria:

* Male and/or female subjects 12 to \< 18 years of age at the time of randomization
* Male and/or female subjects between 18 and 50 years of age (inclusive) at the time of randomization
* Body weight ≥ 36 kg at screening
* Intermittent or mild to moderate persistent asthma for at least the past 3 months prior to study enrollment (as defined by the 2004 Global Initiative for Asthma \[GINA\] guidelines.

Exclusion Criteria:

* Experienced an asthma exacerbation (defined as a disease episode resulting in treatment in an emergency room or urgent care facility, or an episode treated with oral corticosteroids) during the 3 months prior to study enrollment.
* Hospitalized for asthma during the 6 months prior to study enrollment; or ever intubated for the treatment of asthma.
* Use of oral corticosteroids within 3 months prior to study enrollment.

Primary outcomes:
measure: Evaluation of treatment-emergent adverse events, safety and laboratory assessments in adolescent subjects with intermittent or mild to moderate asthma as a measure of safety and tolerability
timeFrame: Participants will be followed for the duration of the study, an expected average of 5 weeks
Secondary outcomes:
measure: Area under the AMG 827 concentration versus time curve (AUC) for times 0 to infinity (AUC 0-inf) and 0 to last sampling time point (AUC 0-tlast), peak plasma concentration (Cmax) and Time to peak plasma concentration (tmax) will be determined for AMG 827
timeFrame: Intermittantly throughout the duration of the study, an expected average of 5 weeks
measure: Evaluation of treatment-emergent adverse events, safety and laboratory assessments in adult subjects with intermittent or mild to moderate asthma as a measure of safety and tolerability
timeFrame: Intermittantly throughout the duration of the study, an expected average of 5 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References: